Investigational drug · Phase 2
ALK201
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Cancer, Advanced Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "ALK201"
First trial start
2024
Oct 24, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALK201", any sponsor or status.
Conditions studied
As listed on its trial records.
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Advanced Cancer
- Advanced Solid Tumors
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ALK201" as an intervention, largest first.
Shanghai Allink Biotherapeutics Co., Ltd.Industry
NCT06656390 · 202 participants (planned) · Start Oct 24, 2024 · Primary completion Oct 22, 2027
Drug: ALK201 · For: Advanced Cancer; Advanced Solid Tumors
Sites: Denver, Colorado; Orlando, Florida; New Orleans, Louisiana · 38 sites in all
- Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.Pivotal-lookingNot yet recruiting
Shanghai Allink Biotherapeutics Co., Ltd.Industry
NCT07742956 · 156 participants (planned) · Start Aug 20, 2026 · Primary completion Dec 31, 2027
Drug: ALK201 for injection; Ivonescimab Injection · For: NSCLC (Advanced Non-small Cell Lung Cancer)
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for NSCLC (Advanced Non-small Cell Lung Cancer)
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- SCTB41Phase 36 trials
Sinocelltech Ltd. · NHL - Non-Hodgkin's Lymphoma, NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Malignant Solid Tumor
- AMT-116Phase 33 trials
Multitude Therapeutics Inc. · Advanced Solid Tumors, Advanced Non-small Cell Lung Cancer (NSCLC), NSCLC (Advanced Non-small Cell Lung Cancer)
- JYP0322Phase 32 trials
Guangzhou JOYO Pharma Co., Ltd · Non Small Cell Lung Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
- ODM-212Phase 22 trials
Orion Corporation, Orion Pharma · Solid Tumours, Mesothelioma, Pancreatic Cancer
- TCC1727Phase 22 trials
Beijing Tide Pharmaceutical Co., Ltd · Patients with Advanced Solid Tumors, Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)
- ALK202Phase 21 trial
Shanghai Allink Biotherapeutics Co., Ltd. · NSCLC (Advanced Non-small Cell Lung Cancer)
- BH-30643Phase 21 trial
BlossomHill Therapeutics · NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.